EPIX - ESSA Pharma Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

ESSA Pharma Inc.

999 West Broadway
Suite 720
Vancouver, BC V5Z 1K5

Full Time Employees25

Key Executives

Dr. David Ross Parkinson M.D.Chief Exec. Officer, Pres and Director329.53kN/A67
Mr. David S. Wood MBA, CPA, CMAChief Financial OfficerN/AN/A60
Mr. Peter A. VirsikChief Operating Officer and Exec. VP60.83kN/A46
Dr. Raymond Andersen Ph.D.Chief Technical Officer, Sec. and DirectorN/AN/A70
Dr. Marianne D. Sadar Ph.D.Chief Scientific Officer and DirectorN/AN/A56
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor. The company was founded in 2009 and is headquartered in Vancouver, Canada.

Corporate Governance

ESSA Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.